New Data Presented at ASTRO 2015 and Published in The Lancet Demonstrate that Accelerated Partial Breast Irradiation (APBI) with Brachytherapy Achieves Favorable Long-Term Efficacy Equivalent to Traditional Whole Breast Irradiation (WBI)
New Data Presented at ASTRO 2015 and Published in The Lancet Demonstrate that Accelerated Partial Breast Irradiation (APBI) with Brachytherapy Achieves Favorable Long-Term Efficacy Equivalent to Traditional Whole Breast Irradiation (WBI)
Excellent/Good Safety and Cosmesis Outcomes Reported
SAN ANTONIO, 19th October, 2015/PR Newswire/ – Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
Additionally, updated results from the PROMIS registry, evaluating 1,374 patients, demonstrated excellent long-term toxicity and cosmetic outcomes among women who underwent APBI brachytherapy.
Commenting on the results, Mitchell Kamrava, M.D., corresponding study author and assistant clinical professor, Department of Radiation Oncology, University of California Los Angeles Jonsson Comprehensive Cancer Center, noted “These compelling data from the GEC-ESTRO and PROMIS registry offer substantial real-world clinical evidence supporting abbreviated interstitial breast cancer treatment and we expect that current treatment guidelines will evolve based on these studies and other forthcoming data.”
MED-00153[00]